Withaferin A: From ayurvedic folk medicine to preclinical anti-cancer drug

Identification of a c-MYB-directed therapeutic for acute myeloid leukemia

“…Despite the relatively poor reported bioavailability of WFA [ 52 ], oral administration significantly impaired AML progression in engrafted mice. This is consistent with previous reports of in vivo WFA activity in numerous disease models [ 27 , 53 ], including a wide range of cancer types [ 54 ]. Thus, although further development of clinical formulations may be necessary, the safety and efficacy profiles of WFA position it as an exciting novel anti-AML therapeutic.…”

Identification of a c-MYB-directed therapeutic for acute myeloid leukemia

“…Despite the relatively poor reported bioavailability of WFA [ 52 ], oral administration significantly impaired AML progression in engrafted mice. This is consistent with previous reports of in vivo WFA activity in numerous disease models [ 27 , 53 ], including a wide range of cancer types [ 54 ]. Thus, although further development of clinical formulations may be necessary, the safety and efficacy profiles of WFA position it as an exciting novel anti-AML therapeutic.…”

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells

“…Based on the duality of its kinome profile, WA seems to be able to both induce apoptotic and ferroptotic cell death. In agreement with this observation, previous studies have reported that WA is able to trigger different cell death modalities based on the cellular context and concentration range used [41,42].…”

Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions

“…Other research indicates direct modulation of RSK, mTOR, AKT by Withaferin A to provide corroborative support for what we are seeing in our work. 71 Nevertheless, we are showing comparable results with the Withaferin A-reduced (25% Withaferin A) Ashwagandha extract, Oncowithanib.…”

Identification of a c-MYB-directed therapeutic for acute myeloid leukemia

“…Despite the relatively poor reported bioavailability of WFA [ 52 ], oral administration significantly impaired AML progression in engrafted mice. This is consistent with previous reports of in vivo WFA activity in numerous disease models [ 27 , 53 ], including a wide range of cancer types [ 54 ]. Thus, although further development of clinical formulations may be necessary, the safety and efficacy profiles of WFA position it as an exciting novel anti-AML therapeutic.…”

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells

“…Based on the duality of its kinome profile, WA seems to be able to both induce apoptotic and ferroptotic cell death. In agreement with this observation, previous studies have reported that WA is able to trigger different cell death modalities based on the cellular context and concentration range used [41,42].…”

Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions

“…Other research indicates direct modulation of RSK, mTOR, AKT by Withaferin A to provide corroborative support for what we are seeing in our work. 71 Nevertheless, we are showing comparable results with the Withaferin A-reduced (25% Withaferin A) Ashwagandha extract, Oncowithanib.…”

Identification of a c-MYB-directed therapeutic for acute myeloid leukemia

“…Despite the relatively poor reported bioavailability of WFA [ 52 ], oral administration significantly impaired AML progression in engrafted mice. This is consistent with previous reports of in vivo WFA activity in numerous disease models [ 27 , 53 ], including a wide range of cancer types [ 54 ]. Thus, although further development of clinical formulations may be necessary, the safety and efficacy profiles of WFA position it as an exciting novel anti-AML therapeutic.…”

Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells

“…Based on the duality of its kinome profile, WA seems to be able to both induce apoptotic and ferroptotic cell death. In agreement with this observation, previous studies have reported that WA is able to trigger different cell death modalities based on the cellular context and concentration range used [41,42].…”

Study of Drug Targets Associated With Oncogenesis and Cancer Cell Survival and the Therapeutic Activity of Engineered Ashwagandha Extract Having Differential Withanolide Constitutions

“…Other research indicates direct modulation of RSK, mTOR, AKT by Withaferin A to provide corroborative support for what we are seeing in our work. 71 Nevertheless, we are showing comparable results with the Withaferin A-reduced (25% Withaferin A) Ashwagandha extract, Oncowithanib.…”